The bill authorizes the administration of epinephrine through various methods, including auto-injectors and nasal sprays, to address severe allergic reactions in schools. It amends existing laws to expand the definition of "medication required for potentially life-threatening conditions" to include epinephrine, while removing the requirement for a prescription for schools to acquire and dispense stock epinephrine auto-injectors. The bill also mandates the development of guidelines for managing students with life-threatening allergies, which will include training for school personnel on the administration of epinephrine and record-keeping for incidents involving severe allergic reactions.

Additionally, the bill provides immunity from liability for individuals and entities administering epinephrine in good faith, ensuring that they are protected from civil or criminal liability for any resulting injuries, except in cases of gross negligence. It also clarifies that the administration of epinephrine does not constitute the practice of medicine. The bill requires the relevant state departments to create necessary rules for implementation and sets an effective date of July 1, 2026, for most provisions, with certain sections taking effect immediately upon the bill's passage.

Statutes affected:
Introduced: 21-4-310, 21-4-316, 33-24-158, 35-4-902, 35-4-903, 35-4-904, 35-4-905, 35-4-906